Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

28

Revenue 2017

Ibrance

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Ibrance was produced by Pfizer.

20 for 2020 – Five pharma leaders to watch in 2020

20 for 2020 – Five pharma leaders to watch in 2020

to 2025 built on the Prevnar franchise, rare disease therapy Vyndaqel (tafamidis), breast cancer therapy Ibrance (palbociclib) and arthritis drug Xeljanz (tofacitinib), among others.

Vyndaqel a bright spot as Pfizer comes under pressure

Vyndaqel a bright spot as Pfizer comes under pressure The company’s fourth-quarter results saw a 9% drop in revenues to $12.69bn, with breast cancer drug Ibrance (palbociclib) and Xeljanz (tofacitinib) for rheumatoid arthritis both growing but missing ... Ibrance was up 15% to $1.28bn in the quarter,

Integrating electronic health records into clinical trials

Integrating electronic health records into clinical trials Pfizer, for example, won an expanded FDA label for breast cancer drug Ibrance on the strength of data from sources including EHRs.

NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata

NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata Ibrance. Pfizer received a positive answer from the cost-effectiveness watchdog, with NICE approving its breast cancer drug Ibrance (palbociclib) for use on the Cancer Drugs Fund. ... Like Ibrance, AZ’s drug will be recommended for use within the CDF

GSK, Pfizer and Sanofi among drugmakers planning price hikes in US

GSK, Pfizer and Sanofi among drugmakers planning price hikes in US This includes its CDK 4/6 inhibitor Ibrance (palbociclib),  which grew by 27% to $1.3bn in the last quarter, and its fast-growing oral JAK inhibitor Xeljanz (tofacitinib).

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics